

Cardiovascular Systems Inc  
Form 8-K  
November 21, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 18, 2013**

**Cardiovascular Systems, Inc.**

**(Exact name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**000-52082**  
**(Commission**

**File Number)**  
**651 Campus Drive**

**41-1698056**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: Cardiovascular Systems Inc - Form 8-K

**St. Paul, Minnesota 55112-3495**

**(Address of Principal Executive Offices and Zip Code)**

**(651) 259-1600**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

In this report, Company, we, us and our refer to Cardiovascular Systems, Inc.

**Item 1.01 Entry Into a Material Definitive Agreement.**

On November 20, 2013, we entered into an underwriting agreement (the Underwriting Agreement ) with Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representative of the underwriters named therein (the Underwriters ), relating to the issuance and sale of 2,608,696 shares of our common stock, par value \$0.001 per share. The shares are to be offered to the public initially at \$30.00 per share (the Public Offering Price ) and to certain dealers selected by the Underwriters at a price that represents a concession not in excess of \$1.08 per share under the Public Offering Price. The Underwriters have agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of \$28.20 per share. The net proceeds to us from this offering are expected to be approximately \$73.4 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering is expected to close on or about November 26, 2013, subject to customary closing conditions. In addition, under the terms of the Underwriting Agreement, we have granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 391,304 shares of common stock.

The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. The offering is being made pursuant to our effective registration statement on Form S-3 (Registration Statement No. 333-191768), including our registration statement on Form S-3 filed pursuant to Rule 462(b) (Registration Statement No. 333-192463), previously filed with the Securities and Exchange Commission and the respective prospectus supplements thereunder. The Underwriting Agreement is filed as Exhibit 1.1 to this report, and the description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Fredrikson & Byron P.A. relating to the legality of the issuance and sale of the shares in the offering is attached as Exhibit 5.1 hereto.

**Item 8.01 Other Events.**

On November 18, 2013, we issued a press release announcing that we had commenced the offering. On November 20, 2013, we issued a press release announcing that we had priced the offering. The press releases are attached as Exhibits 99.1 and 99.2 hereto, respectively.

**Item 9.01 Financial Statements and Exhibits.  
(d) Exhibits**

**Exhibit**

<b>Number</b>	<b>Description</b>
1.1	Underwriting Agreement, dated November 20, 2013
5.1	Opinion of Fredrikson & Byron P.A.

Edgar Filing: Cardiovascular Systems Inc - Form 8-K

- 23.1** Consent of Fredrikson & Byron P.A. (included in Exhibit 5.1)
- 99.1** Press Release dated November 18, 2013
- 99.2** Press Release dated November 20, 2013

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 21, 2013

**CARDIOVASCULAR SYSTEMS, INC.**

By: /s/ Laurence L. Betterley  
Laurence L. Betterley  
Chief Financial Officer

**INDEX TO EXHIBITS**

**Exhibit**

<b>Number</b>	<b>Description</b>
<b>1.1</b>	Underwriting Agreement, dated November 20, 2013
<b>5.1</b>	Opinion of Fredrikson & Byron P.A.
<b>23.1</b>	Consent of Fredrikson & Byron P.A. (included in Exhibit 5.1)
<b>99.1</b>	Press Release dated November 18, 2013
<b>99.2</b>	Press Release dated November 20, 2013